Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced the appointment
of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr.
Zeldin brings to Acceleron more than two decades of clinical,
regulatory and industry experience, most recently serving as CMO of
Belgium-based Ablynx NV.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180705005474/en/
Robert K. Zeldin, M.D., named Chief
Medical Officer, Acceleron Pharma Inc.
“Robert has built an impressive career, holding a variety of
leadership positions across clinical development, regulatory, and
medical affairs functions,” said Habib Dable, Chief Executive
Officer of Acceleron. “He’s joining us at a critical time for the
company as we advance our lead product candidate, luspatercept, in
multiple hematologic indications. Moreover, we have ongoing Phase 2
programs with our key, wholly-owned pipeline assets in
neuromuscular and pulmonary diseases. Robert’s breadth and depth of
experience should prove immensely valuable in executing on our
clinical development goals.”
As a member of the Executive Committee at Ablynx, Dr. Zeldin
contributed to the development and implementation of the overall
corporate strategy. He was responsible for the Medical, Regulatory,
Pharmacovigilance, Clinical Operations, Biostatistics, and Data
Management functions and led a team of 60. He joined Ablynx from
French pharmaceutical firm Stallergenes SA, where he was Senior
Vice President and Head of Global Clinical Development. Earlier, he
worked for five years at Novartis Pharmaceuticals, the final three
as Vice President and U.S. Medical Franchise Head, Respiratory and
Dermatology. Dr. Zeldin’s career in industry began at Merck, where
he spent seven years in progressively strategic roles in worldwide
regulatory affairs and clinical development, rising to the position
of Senior Director of Clinical Development with responsibility for
products in the respiratory, cardiovascular, and infectious disease
therapeutic areas.
“It’s a privilege to join the Acceleron team in the pursuit of
novel therapies for serious and rare diseases with significant
unmet medical need,” said Dr. Zeldin. “Seldom does one have an
opportunity to contribute to the development and potential launch
of medicines in multiple therapeutic areas for diverse patient
populations, all of whom are vastly underserved by current
options.”
Prior to his work in industry, Dr. Zeldin served as a Medical
Officer at the U.S. Food & Drug Administration’s Center for
Biologics Evaluation and Research, assessing efficacy and safety
data from the clinical development of allergy-related therapies,
vaccines, and orphan products. He also spent several years in
clinical practice treating patients with allergic, asthmatic, and
immunologic disorders. He holds a B.A. with honors from Johns
Hopkins University and an M.D. from Tufts University School of
Medicine. His postdoctoral training included Residency in Internal
Medicine at University Health Center of Pittsburgh and Fellowship
in Allergy and Clinical Immunology at Johns Hopkins University
School of Medicine.
Dr. Zeldin succeeds longtime Acceleron CMO, Matthew Sherman,
M.D., who earlier this year announced his planned retirement. Dr.
Sherman will remain on staff until the anticipated mid-2018 release
of topline Phase 3 data from the BELIEVE trial of luspatercept in
beta-thalassemia patients, and will then serve in an advisory
capacity for one year thereafter.
About Acceleron
Acceleron is a Cambridge, MA-based, clinical-stage
biopharmaceutical company dedicated to the discovery, development,
and commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with sotatercept in pulmonary arterial hypertension.
For more information, please
visit www.acceleronpharma.com/. Follow Acceleron on Social
Media: @AcceleronPharma and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's strategy, future plans and prospects, including
statements regarding the development of the Company's compounds,
the timeline for clinical development and regulatory approval of
the Company’s compounds and the expected timing for reporting of
data from ongoing clinical trials. The words "anticipate,"
"believe," "could," "estimate," "expect," "goal," "intend," "may,"
"plan," "potential," "project," "should," "target," "will,"
"would," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to, that preclinical
testing of the Company's compounds and data from clinical trials
may not be predictive of the results or success of ongoing or later
clinical trials, that the results of any clinical trial may not be
predictive of the results or success of other clinical trials of
the same product candidate, that the development of the Company's
compounds will take longer and/or cost more than planned, that the
Company will be unable to successfully complete the clinical
development of the Company’s compounds, that the Company may be
delayed in initiating, enrolling or completing any clinical trials,
and that the Company's compounds will not receive regulatory
approval or become commercially successful products. These and
other risks and uncertainties are identified under the heading
"Risk Factors" included in the Company's most recent Annual Report
on Form 10-K, and other filings that the Company has made and may
make with the SEC in the future.
The forward-looking statements contained in this press release
are based on management’s current views, plans, estimates,
assumptions and projections with respect to future events, and the
Company does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180705005474/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsOrCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsOrMedia:Matt Fearer, 617-301-9557Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
